Paul Jeng
Stock Analyst at Guggenheim
(2.96)
# 1,359
Out of 5,146 analysts
7
Total ratings
100%
Success rate
48.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Buy | $50 | $31.90 | +56.74% | 2 | Feb 18, 2026 | |
| ADAG Adagene | Initiates: Buy | $9 | $3.11 | +189.86% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.13 | +87.56% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $32.04 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $2.28 | +119.30% | 1 | Sep 18, 2025 |
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Buy
Price Target: $50
Current: $31.90
Upside: +56.74%
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $3.11
Upside: +189.86%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.13
Upside: +87.56%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $32.04
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $2.28
Upside: +119.30%